查詢結果分析
來源資料
相關文獻
- 肺癌的液態活檢
- 循環腫瘤細胞捕捉技術在癌症診斷之應用
- Lung Cancer in Pregnancy: Report of Two Cases
- Ifosfamide-Based Chemotherapy for Previously Treated Lung Cancer Patients
- 化學防癌與肺癌
- 非小細胞肺癌術前輔助性化學治療的經驗
- Outcome of Patients with Lung Cancer Treated with Mechanical Ventilation for Respiratory Failure
- 不吸菸婦女肺癌研究
- Docetaxel (Taxotere)--治療乳癌與肺癌的新藥
- The Evolution of the Diagnosis and Understanding of Lung Cancer Pathology: Living Through an Epoch
頁籤選單縮合
題名 | 肺癌的液態活檢=Liquid Biopsy in Lung Cancer |
---|---|
作者 | 楊福雄; 湯旭南; | 書刊名 | 內科學誌 |
卷期 | 28:6 2017.12[民106.12] |
頁次 | 頁334-343 |
分類號 | 415.468 |
關鍵詞 | 肺癌; 腫瘤的異質性; 液態活檢; 循環腫瘤去氧核醣核酸; 循環腫瘤細胞; 腫瘤化血小板; 胞外泌體; Lung cancer; Tumor heterogenicity; Liquid biopsy; Circulating tumor DNA; ctDNA; Circulating tumor cell; CTC; Tumor educated platelets; TEP; Exosomes; |
語文 | 中文(Chinese) |
中文摘要 | 肺癌(lung cancer)是全球相關癌症致死的主要原因之一,大約佔了癌症相關死亡人數的四分之一。推究主要原因是發現時大部分都是晚期,就算目前推行的低劑量胸部電腦斷層檢查能降低相關肺癌致死率20%,但是高的偽陽性導致不必要的侵入性組織切片檢查。隨著分子醫學技術的發展,目前針對癌症的檢查已經從傳統的病理檢驗擴展到基因分子醫學的領域,了解到越來越多的疾病,包括癌症也是異質性的疾病(tumor heterogenicity),所以單一次的組織病理切片檢查不能表達整個腫瘤的樣貌;液態活檢(liquid biopsy)可以補充組織病理檢驗提供非侵入性、即時性、重複性的檢查,本文中將介紹相關的生物標記:循環腫瘤去氧核醣核酸(circulating tumor DNA, ctDNA)、循環腫瘤細胞(circulating tumor cell, CTC)、腫瘤化血小板(tumor educated platelets, TEP)及胞外泌體(exosomes),最後在探討液態活檢在肺癌的臨床相關運用。 |
英文摘要 | Lung cancer is the leading cause of deaths from cancer worldwide, accounting for almost one-quarter of fatalities. The overwhelming majority of these victims die due to a late diagnosis. Despite the powerful tool with low-dose computed tomography (LDCT) reduces the risk of death by 20%, the false positive finding of LDCT or overdiagnosis could lead to unnecessary invasive tissue biopsy and harmful management. With the advancement in the identification of molecular and protein-based tumor biomarkers, the current cancer screen has been extended from traditional pathological examination to genomics in order to understand more and more pathogenesis of the heterogenous characteristic in cancer. A single tissue biopsy can't represent the appearance of the entire tumor. However, liquid biopsy can complement the histopathological examination to provide a noninvasive, immediate and reproducible specimen. In this paper, we introduce the relevant biomarkers in liquid biopsy: circulating tumor DNA, circulating tumor cell, tumor educated platelets, and exosomes. Finally, we discuss the incorporation of liquid biopsy and clinical practice of lung cancer. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。